NOGO-A Neutralizing Immunoglobulins for the Treatment of Neurological Diseases

Abstract

The present invention relates to antibodies to NOGO, pharmaceutical formulations containing them and to the use of such antibodies in the treatment and/or prophylaxis of neurological diseases/disorders.

1 .- 30 . (canceled) 
     
     
         31 . A monoclonal antibody which binds to and neutralises human NOGO A, the monoclonal antibody comprising a heavy chain variable region which has the sequence of SEQ ID NO:77, with the exception that the amino acid residue at position 48 of SEQ ID NO:77 is substituted with isoleucine, the amino acid residue at position 67 of SEQ ID NO:77 is substituted with lysine and the amino acid residues at position 68 and 79 of SEQ ID NO:77 are substituted with alanine; or an analog of said antibody, wherein the analog comprises an amino acid modification within a CDR of said heavy chain. 
     
     
         32 . The monoclonal antibody of  claim 31 , wherein said analog comprises an amino acid modification within CDRH1 of said heavy chain. 
     
     
         33 . The monoclonal antibody of  claim 31 , wherein said analog comprises an amino acid modification within CDRH2 of said heavy chain. 
     
     
         34 . The monoclonal antibody of  claim 31 , wherein said analog comprises an amino acid modification within CDRH3 of said heavy chain. 
     
     
         35 . The monoclonal antibody of  claim 31 , comprising a light chain variable region which has the sequence of SEQ ID NO:23.